Literature DB >> 33119819

Dying to see you? Deaths on a clinical genetics waiting list in the Republic of Ireland; what are the consequences?

Lisa Bradley1, Sally Ann Lynch2,3.   

Abstract

Attempts to put a value on a clinical genetic consultation are challenging as outcome measures are not easily quantified. One technique is to consider the negative consequences to a referred patient who is never seen. In order to estimate possible negative effects and by default the value of a genetics consultation; we sought to identify the consequences both to the proband, who died awaiting appointment, and their relatives. We audited 45 referrals to our service who died on our waiting list since 2008. Of these, 39/45 were new referrals, and the remainder, 6/45, died awaiting a follow up appointment. Relatives from 14/45 (31%) families have been counselled since the proband's death. We estimated a minimal total of 207 living first degree relatives to 45 probands. The majority (30/45) were referred for cancer risk estimation (1 predictive, 29 diagnostic), 11 developmental delay/dysmorphology referrals, 3 cardiac genetic referrals, (2 predictive testing, 1 segregation analysis) and 1 a referral for early onset dementia. The deaths of 17/45 cases were judged by us as having potentially significantly impacted the health of 76 first-degree relatives; 13/45 have potentially moderately impacted the health of 57 first-degree relatives; 12/45 posed a minimal impact to their relatives; and in 3/45 cases families were fully counselled. For each proband, significantly or moderately negatively impacted (n = 30), they have a minimum of 4.4 first-degree relatives, range 1-11, total = 133.

Entities:  

Keywords:  Clinical genetics; Deaths on a waiting list; First degree relatives; Time to wait

Year:  2020        PMID: 33119819     DOI: 10.1007/s12687-020-00491-3

Source DB:  PubMed          Journal:  J Community Genet        ISSN: 1868-310X


  8 in total

1.  Why patients do not attend for their appointments at a genetics clinic.

Authors:  L Humphreys; A G Hunter; A Zimak; A O'Brien; Y Korneluk; M Cappelli
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

2.  Cascade screening in BRCA1/2 mutation carriers.

Authors:  N Cody; A Green; T McDevitt; S A Lynch
Journal:  Ir Med J       Date:  2008-05

3.  Prevention of sudden death in adolescent athletes: Incremental diagnostic value and cost-effectiveness of diagnostic tests.

Authors:  Gonzalo Grazioli; Maria Sanz de la Garza; Barbara Vidal; Silvia Montserrat; Georgia Sarquella-Brugada; Ramon Pi; Lluis Til; Josep Gutierrez; Josep Brugada; Marta Sitges
Journal:  Eur J Prev Cardiol       Date:  2017-06-02       Impact factor: 7.804

Review 4.  The importance of genetic counselling in genome-wide sequencing.

Authors:  Alison M Elliott; Jan M Friedman
Journal:  Nat Rev Genet       Date:  2018-12       Impact factor: 53.242

5.  Towards establishing consistency in triage in a tertiary specialty.

Authors:  Terri Patricia McVeigh; Deirdre Donnelly; Maryam Al Shehhi; Elizabeth A Jones; Alexandra Murray; Sarah Wedderburn; Mary Porteous; Sally Ann Lynch
Journal:  Eur J Hum Genet       Date:  2019-01-08       Impact factor: 4.246

6.  Wide disparity of clinical genetics services and EU rare disease research funding across Europe.

Authors:  Sally Ann Lynch; Isabella Borg
Journal:  J Community Genet       Date:  2015-11-04

7.  What motivates interest in attending a familial cancer genetics clinic?

Authors:  L Fraser; S Bramald; C Chapman; C Chu; V Cornelius; F Douglas; A Lucassen; A Nehammer; S Sutton; M Trivella; S Hodgson
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.446

  8 in total
  3 in total

1.  A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.

Authors:  Terri Patricia McVeigh; Karl J Sweeney; Donal J Brennan; Una M McVeigh; Simon Ward; Ann Strydom; Sheila Seal; Katherine Astbury; Paul Donnellan; Joanne Higgins; Maccon Keane; Michael J Kerin; Carmel Malone; Pauline McGough; Ray McLaughlin; Michael O'Leary; Margaret Rushe; Michael Kevin Barry; Geraldine MacGregor; Michael Sugrue; Ala Yousif; Dhafir Al-Azawi; Eileen Berkeley; Terence J Boyle; Elizabeth M Connolly; Carmel Nolan; Elaine Richardson; Claire Giffney; Samantha B Doyle; Sheila Broderick; William Boyd; Ruaidhri McVey; Thomas Walsh; Michael Farrell; David J Gallagher; Nazneen Rahman; Angela J George
Journal:  Fam Cancer       Date:  2022-08-27       Impact factor: 2.446

2.  Duplication of referral, a tsunami of paper: how much does it cost the Irish health services?

Authors:  Nicola Walsh; Lisa Malone; Sally Ann Lynch
Journal:  Ir J Med Sci       Date:  2022-01-10       Impact factor: 1.568

3.  A qualitative reflexive thematic analysis into the experiences of being identified with a BRCA1/2 gene alteration: "So many little, little traumas could have been avoided".

Authors:  Nikolett Zsuzsanna Warner; AnnMarie Groarke
Journal:  BMC Health Serv Res       Date:  2022-08-06       Impact factor: 2.908

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.